Top | S-Quatre Corporation

エディタV2

Power of child’s stem cells to Fight incurable diseases

お知らせ：表示

2025/07/22：New Results from the joint research with Hamamatsu University School of Medicine to be presented at the 31st Annual Meeting of Japan Society of Gene and Cell Therapy (JSGCT2025): At the 31st Annual Meeting of Japan Society of Gene and Cell Therapy (JSGCT2025), scheduled to start on July 23rd in 2025, Hamamatsu University School of Medicine -our collaborative research partner- will present two new research findings related to the development of novel therapies for brain tumors using SHED (stem cells from human exfoliated deciduous teeth).

Presentation 1: Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against glioblastoma stem cell

Presentation 2: Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas

The 31st Annual Meeting of Japan Society of Gene and Cell Therapy (JSGCT2025) website
https://square.umin.ac.jp/jsgct2025/en/index.html

Related releases
November 7th, 2022
Announcement of publication of the research articles in collaboration with Hamamatsu University School of Medicine - Proof of concept of the potential therapeutic application of next generation SHED for brain cancer -

November 28th, 2022
Announcement of publication of the third research article in collaboration with Hamamatsu University School of Medicine - Proof of concept of the potential therapeutic application of next generation SHED for brain cancer –

エディタV2

Aiming for the World's First Cell Therapy Using SHED

Research of regenerative medicine using various types of cells has been actively performed around the world. We focused on SHED “stem cells from a child’s tooth” and are strenuously conducting the research and development to realize a new cell therapeutics for various intractable diseases.

エディタV2

S-Quatre^® – Stable Manufacturing and Supply System of Cell Banks for Cell Therapeutics

Practical application of cell therapeutics needs to stably procure donor tissue sources, manufacture cell banks, and supply them. We established a stable manufacturing and supply system of SHED banks named S-Quatre^® by our own technology and network, composing a platform of the development of our cell therapeutics.